to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
A Randomized, Double-Blind, International Multi-Centre, Phase III Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Sponsor: Shanghai Henlius Biotech
This PHASE3 trial investigates Triple Negative Breast Cancer and is currently actively recruiting participants. Shanghai Henlius Biotech leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Henlius Biotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.